Key facts
- Tenaya has reported interim data from its gene therapy trial.
- The trial is for a rare heart condition.
- The study is evaluating the treatment's efficacy and safety.
Tenaya has announced the release of interim data from its ongoing clinical trial for a rare heart condition. The trial is designed to assess the efficacy and safety of the experimental gene therapy. Further details on the specific outcomes of the interim data are expected to be disclosed as the trial progresses.